Investments, Funding & Disinvestment

The alliance positions WellSpan as a key innovation partner for Philips, enabling the two institutions to co-develop and validate new digital health tools in real-world clinical environments.

Under the agreement, EGT will oversee the rollout of Koios DS™ Breast and Koios DS™ Thyroid across key GCC markets, including the United Arab Emirates, Saudi Arabia, and Qatar.

The new hospital forms a central pillar of a wider specialised medical city focused on women and children’s health.

The donation includes 108 electric obstetric theatre beds, along with specialised equipment for women’s cancer screening, diagnosis, and treatment.

Under the new system, Emiratis will be able to access healthcare services anywhere in the country regardless of their emirate of residence.

Under the agreement, Lilly will obtain exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialise sonefpeglutide, a long-acting GLP-2 analogue.

Under the agreement, Servier will take control of Edgewise Therapeutics’ muscular dystrophy portfolio, including its lead candidate sevasemten.

The initiative focuses on expanding genomic sequencing capacity, improving molecular diagnostics, and enhancing real-time disease surveillance across African health systems.

The financing will also reinforce critical pillars of outbreak control, including disease surveillance, laboratory diagnostics, infection prevention and control, and cross-border coordination mechanisms.

The plan targets key pillars of outbreak control, including emergency coordination, disease surveillance, laboratory diagnostics, infection prevention and control, and clinical case management.